# PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

> **NCT03699631** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 29 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03699631
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-06
- **Primary completion:** 2022-03-02
- **Final completion:** 2023-04-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699631, "PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03699631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*